Overview

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML

Status:
Not yet recruiting

Trial end date:
2025-02-01

Target enrollment:

Participant gender:

Summary

The study "GALAXY33" is an open-label, prospective, nonrandomized, one arm phase I clinical trial in which patients with relapsed AML after allogeneic hematopoietic stem cell transplantation will be transplanted with CD33-deleted CD34+ HSC derived from the initially matched family donor.

Phase:

Phase 1

Details

Lead Sponsor:

German Cancer Research Center

Collaborators:

University Hospital Dresden
University Hospital Heidelberg

Treatments:

Gemtuzumab